MOA of antidiabetic drugs

Question 1

this drug decreases gluconeogensis and increases peripheral utilisation of glucose by increasing insulin sensitivity

Answer 1

metformin

Question 2

metformin

Answer 2

this drug decreases gluconeogensis and increases peripheral utilisation of glucose by increasing insulin sensitivity

Question 3

this drug class increase the amount of insulin your pancreas makes and thus this lowers your blood sugar.

Answer 3

SUs

Question 4

SUs

Answer 4

this drug class increase the amount of insulin your pancreas makes and thus this lowers your blood sugar.

Question 5

this drug class mainly by augmenting insulin secretion and consequently are effective only when some residual pancreatic beta-cell activity is present; during long-term administration they also have an extrapancreatic action.

Answer 5

SUs

Question 6

gliptins inhibits …. to increase insulin secretion and lower glucagon secretion.

Answer 6

DDP4i

Question 7

DDP4i

Answer 7

gliptins inhibits DDP4i to increase insulin secretion and lower glucagon secretion.

Question 8

this drug reduces peripheral insulin resistance, leading to a reduction of blood-glucose concentration.

Answer 8

pioglitazone

Question 9

pitoglitazone

Answer 9

reduces peripheral insulin resistance, leading to a reduction of blood-glucose concentration.

Question 10

this drug class reduce glucose reabsorption and increase urinary glucose excretion.

Answer 10

sglt2i: they reversibly inhibits SGLT2 in the renal proximal convoluted tubule to reduce glucose reabsorption and increase urinary glucose excretion.

Question 11

SGLT2i

Answer 11

Reversibly inhibits sodium-glucose co-transporter 2 (SGLT2) in the renal proximal convoluted tubule to reduce glucose reabsorption and increase urinary glucose excretion.

Question 12

glp1

Answer 12

bind to GLP-1 (glucagon-like peptide-1) receptor to increase insulin secretion, suppress glucagon secretion, and slow gastric emptying.

Question 13

this drug class increases insulin secretion, suppresses glucagon secretion and slows gastric emptying

Answer 13

GLP-1 (glucagon-like peptide-1) receptor to increase insulin secretion, suppress glucagon secretion, and slow gastric emptying.